References
- 1. D. H. Maurice, H. Ke, F. Ahmad, Y. Wang, J. Chung and V. C. Manganiello, Advances in targeting cyclic nucleotide phosphodiesterases, Nat. Rev. Drug Discov. 13 (2014) 290-314; DOI: 10.1038/ nrd4228.
- 2. S. H. Francis, M. A. Blount and J. D. Corbin, Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions, Physiol. Rev. 91 (2011) 651-690; DOI: 10.1152/ physrev.00030.2010.
- 3. C. D. Manning, M. Burman, S. B. Christensen, L. B. Cieslinski, D. M. Essayan, M. Grous, T. J. Torphy and M. S. Barnette, Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B, Br. J. Pharmacol. 128 (1999) 1393-1398; DOI: 10.1038/sj.bjp.0702911.
- 4. D. Peter, S. L. Jin, M. Conti, A. Hatzelmann and C. Zitt, Differential expression and function of phosphodiesterase 4 (PDE4) subtypes in human primary CD4+ T cells: predominant role of PDE4D, J. Immunol. 178 (2007) 4820-4831; DOI: 10.4049/jimmunol.178.8.4820.
- 5. P. Wang, P. Wu, K. M. Ohleth, R. W. Egan and M. M. Billah, Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils, Mol. Pharmacol. 56 (1999) 170-174; DOI: 10.1124/mol.56.1.170.
- 6. O. Suzuki, K. Mizukami, M. Etori, Y. Sogawa, N. Takagi, H. Tsuchida, K. Morimoto, T. Goto, T. Yoshino, T. Mikkaichi, K. Hirahara, S. Nakamura and H. Maeda, Evaluation of the therapeutic index of a novel phosphodiesterase 4B-selective inhibitor over phosphodiesterase 4D in mice, J. Pharmacol. Sci. 123 (2013) 219-226; DOI: 10.1254/jphs.13103FP.
- 7. I. Cloez-Tayarani, A. F. Petit-Bertron, H. D. Venters and J. M. Cavaillon, Differential effect of serotonin on cytokine production in lipopolysaccharide-stimulated human peripheral blood mononuclear cells: involvement of 5-hydroxytryptamine2A receptors, Int. Immunol. 15 (2003) 233-240; DOI: 10.1093/intimm/dxg027.
- 8. G. Vacca G. W. J. Randerath and A. Gillissen, Inhibition of granulocyte migration by tiotropium bromide, Respir. Res. 12 (2011) article 24; DOI: 10.1186/1465-9921-12-24.
- 9. U. Prabhakar, D. Lipshutz, J. O. Bartus, M. J. Slivjak, E. F. Smith, J. C. Lee and K. M. Esser, Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor, Int. J. Immunopharmacol. 16 (1994) 805-816; DOI: 10.1016/0192-0561(94)90054-x.
- 10. T. Yoshimura, C. Kurita, T. Nagao, E. Usami, T. Nakao, S. Watanabe, J. Kobayashi, F. Yamazaki, H. Tanaka and H. Nagai, Effects of cAMP-phosphodiesterase isozyme inhibitor on cytokine production by lipopolysaccharide-stimulated human peripheral blood mononuclear cells, Gen. Pharmacol. 29 (1997) 633-638; DOI: 10.1016/S0306-3623(96)00580-0.
- 11. M. D. Houslay, Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown, Trends Biochem. Sci. 35 (2010) 91-100; DOI: 10.1016/j.tibs.2009.09.007.